Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Denosumab biosimilar by Celltrion for Osteoporosis: Likelihood of Approval
Denosumab biosimilar is under clinical development by Celltrion and currently in Phase I for Osteoporosis. According to GlobalData, Phase I...
Omalizumab biosimilar by Celltrion for Allergic Asthma: Likelihood of Approval
Omalizumab biosimilar is under clinical development by Celltrion and currently in Pre-Registration for Allergic Asthma. According to GlobalData, Pre-Registration drugs...
Omalizumab biosimilar by Celltrion for Food Allergy: Likelihood of Approval
Omalizumab biosimilar is under clinical development by Celltrion and currently in Pre-Registration for Food Allergy. According to GlobalData, Pre-Registration drugs...
Omalizumab biosimilar by Celltrion for Nasal Polyps (Nasal Polyposis): Likelihood of Approval
Omalizumab biosimilar is under clinical development by Celltrion and currently in Pre-Registration for Nasal Polyps (Nasal Polyposis). According to GlobalData,...
Omalizumab biosimilar by Celltrion for Rhinosinusitis: Likelihood of Approval
Omalizumab biosimilar is under clinical development by Celltrion and currently in Pre-Registration for Rhinosinusitis. According to GlobalData, Pre-Registration drugs for...
Omalizumab biosimilar by Celltrion for Chronic Urticaria Or Hives: Likelihood of Approval
Omalizumab biosimilar is under clinical development by Celltrion and currently in Pre-Registration for Chronic Urticaria Or Hives. According to GlobalData,...
Denosumab biosimilar by Celltrion for Bone Disorders: Likelihood of Approval
Denosumab biosimilar is under clinical development by Celltrion and currently in Phase I for Bone Disorders. According to GlobalData, Phase...
Aflibercept biosimilar by Celltrion for Age Related Macular Degeneration: Likelihood of Approval
Aflibercept biosimilar is under clinical development by Celltrion and currently in Pre-Registration for Age Related Macular Degeneration. According to GlobalData,...
Ustekinumab biosimilar by Celltrion for Psoriatic Arthritis: Likelihood of Approval
Ustekinumab biosimilar is under clinical development by Celltrion and currently in Pre-Registration for Psoriatic Arthritis. According to GlobalData, Pre-Registration drugs...
Rituximab biosimilar by Celltrion for Primary CNS Lymphoma: Likelihood of Approval
Rituximab biosimilar is under clinical development by Celltrion and currently in Phase II for Primary CNS Lymphoma. According to GlobalData,...
Ustekinumab biosimilar by Celltrion for Ulcerative Colitis: Likelihood of Approval
Ustekinumab biosimilar is under clinical development by Celltrion and currently in Pre-Registration for Ulcerative Colitis. According to GlobalData, Pre-Registration drugs...
Denosumab biosimilar by Celltrion for Post Menopausal Osteoporosis: Likelihood of Approval
Denosumab biosimilar is under clinical development by Celltrion and currently in Pre-Registration for Post Menopausal Osteoporosis. According to GlobalData, Pre-Registration...
Tocilizumab biosimilar by Celltrion for Rheumatoid Arthritis: Likelihood of Approval
Tocilizumab biosimilar is under clinical development by Celltrion and currently in Pre-Registration for Rheumatoid Arthritis. According to GlobalData, Pre-Registration drugs...
Regdanvimab by Celltrion for Coronavirus Disease 2019 (COVID-19): Likelihood of Approval
Regdanvimab is under clinical development by Celltrion and currently in Phase II for Coronavirus Disease 2019 (COVID-19). According to GlobalData,...
Infliximab biosimilar by Celltrion for Coronavirus Disease 2019 (COVID-19): Likelihood of Approval
Infliximab biosimilar is under clinical development by Celltrion and currently in Phase II for Coronavirus Disease 2019 (COVID-19). According to...
Denosumab biosimilar by Celltrion for Osteoporosis: Likelihood of Approval
Denosumab biosimilar is under clinical development by Celltrion and currently in Phase I for Osteoporosis. According to GlobalData, Phase I...
Ocrelizumab biosimilar by Celltrion for Relapsing Remitting Multiple Sclerosis (RRMS): Likelihood of Approval
Ocrelizumab biosimilar is under clinical development by Celltrion and currently in Phase III for Relapsing Remitting Multiple Sclerosis (RRMS). According...
Risk adjusted net present value: What is the current valuation of Celltrion's Denosumab biosimilar?
Denosumab biosimilar is a monoclonal antibody commercialized by Celltrion, with a leading Pre-Registration program in Post Menopausal Osteoporosis. According to...